Kiniksa Pharmaceuticals International plc Class A (KNSA) receives a Roarable Rating of D+ (Sell) and flashes a Red SELL / AVOID warning (64/100 RQD Confidence). Our SEC filing scanner spotted paper earnings outpacing real operating cash flow (+0.0% (NI vs OCF)) while unpaid customer invoices grew—a classic sign to step aside until cash flow catches up.
Kiniksa Pharmaceuticals International plc Class A (KNSA) surged +2.50% to $97.56 as options desks priced 58% call premium vs. 42% put protection around the $96 max-pain magnet. Accounting Warning: Paper earnings outpaced operating cash flow (+0.0% (NI vs OCF)) as receivables rose.
JP Morgan analyst Anupam Rama maintains Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Overweight and raises the price target from $107 to $122.
The stock market saw the major indexes ultimately fall for the week as Google, Amazon, Intel and ServiceNow led a tech wreck. But many sectors thrived.
Goldman Sachs analyst Paul Choi maintains Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Buy and raises the price target from $90 to $101.
Wedbush analyst David Nierengarten maintains Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Outperform and raises the price target from $99 to $102.
Wells Fargo analyst Yanan Zhu maintains Kiniksa Pharmaceuticals (NASDAQ:KNSA) with a Overweight and raises the price target from $87 to $110.
Kiniksa Pharmaceuticals stock exploded 22.2% higher to US$89.20 on Wednesday after traders digested fresh Q3 2026 results. The move caps a strong recent run, yet the real story sits in the earnings print itself. ARCALYST
Profit growth is outpacing revenue gains, giving the company firepower to advance pipeline candidates without diluting shareholders.
Moby summary of Kiniksa Pharmaceuticals, Ltd.'s Q3 2026 earnings call
ARCALYST revenue surged 58% year-over-year as the company raised full-year guidance.
Kiniksa Pharmaceuticals International (NASDAQ:KNSA) raised its full-year 2026 revenue guidance after reporting third-quarter ARCALYST revenue growth of 58% year over year, as the company continued to expand use of the dr
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. +60.1% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on KNSA today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for KNSA. Explore sector supply chains on /butterfly.
Why KNSA Stock surged +2.50% Today — RQD Quant Desk Flash. Accounting Warning: Paper earnings outpaced operating cash flow (+0.0% (NI vs OCF)) as receivables rose.